HUTCHMED (China) (HMDCF) EBITDA Margin (2015 - 2021)

HUTCHMED (China)'s (HMDCF) quarterly EBITDA Margin came in at 172.21% in Q4 2021, down 150.71% quarter-over-quarter from 339.61% in Q3 2021.

Analysis

HUTCHMED (China) (HMDCF) EBITDA Margin (2015 - 2021) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported EBITDA Margin for 6 consecutive years, with 172.21% the latest figure, recorded in Q4 2021.

On a quarterly basis, EBITDA Margin changed N/A year-over-year to 172.21% in Q4 2021; TTM through Dec 2021 was 20.62%, a N/A change from a year earlier, with the FY2025 full-year figure at 7.14%, down 20.0% from the prior year.
EBITDA Margin was 172.21% for Q4 2021 at HUTCHMED (China), down from 339.61% in the prior quarter.
Over five years, EBITDA Margin peaked at 339.61% in Q3 2021 and troughed at 303.37% in Q4 2018.
A 4-year average of 18.22% and a median of 11.33% in 2018 frame the typical range for EBITDA Margin.
Across the five-year window, EBITDA Margin plunged 37387 bps in 2019 and soared 31422 bps in 2020, its largest moves.
Over 4 years, EBITDA Margin stood at 303.37% in 2018, then soared by 76 bps to 72.05% in 2019, then surged by 236 bps to 98.23% in 2020, then plunged by 275 bps to 172.21% in 2021.
The last three EBITDA Margin figures came in at 172.21% (Q4 2021), 339.61% (Q3 2021), and 103.69% (Q2 2021), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Amgen	211.50 Bn	197.51 Bn	7.24 Bn	34.95%
2	Gilead Sciences	181.29 Bn	178.11 Bn	6.22 Bn	-133.21%
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn	37.40%
4	Regeneron Pharmaceuticals	82.55 Bn	74.56 Bn	3.93 Bn	30.15%
5	Argenx Se	61.65 Bn	56.47 Bn	1.37 Bn	32.54%
6	Moderna	54.65 Bn	49.52 Bn	52.00 Mn	-562.07%
7	Alnylam Pharmaceuticals	34.18 Bn	30.87 Bn	992.69 Mn	17.93%
8	Biogen	31.36 Bn	30.07 Bn	1.96 Bn	-23.56%
9	Roivant Sciences	30.01 Bn	30.01 Bn	1.16 Mn	-25,380.93%
10	HUTCHMED (China)	376.85 Mn	391.04 Mn	-	-

Historic Data

Download Data